Clinical Trial Update: RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating HS006 (RHCACD20MA) in combination with CHOP (Hi-CHOP) for previously untreated diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• HS006 (RHCACD20MA)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED